皮肤黑色素瘤诊断的活检需治数指标评估:系统综述与Meta分析
报告的NNB范围为2.2至287,加权平均NNB为15.6;排除特定研究设计后,全球临床医生加权平均NNB为14.8,皮肤科医生为7.5,澳大利亚全科医生为14.6,美国皮肤科执业者(含皮肤科医生和高级实践专业人员)为13.2。研究提示NNB在全球范围差异大且缺乏标准化。
要点
- 全球皮肤黑色素瘤诊断的NNB差异大,范围2.2至287,加权平均15.6。
- 皮肤科医生加权平均NNB为7.5,低于全科医生和美国皮肤科执业者的13.2-14.6。
- 研究分层显示活检中黑色素瘤比例:所有皮肤肿瘤活检为4%,黑色素细胞肿瘤病理 review 和临床怀疑黑色素瘤均为12%。
核心结论
- 现有皮肤黑色素瘤NNB在全球范围差异大,缺乏指标定义和报告的标准化,且与临床医生特征相关。
- 美国临床医生的NNB可能需要进一步探索。
主要发现
- 报告的NNB范围为2.2至287,所有纳入出版物的加权平均NNB为15.6。
- 排除因数据特征可变而以所有活检肿瘤为结构的研究后,NNB范围为2.2至30.5,全球所有临床医生加权平均NNB为14.8。
- 皮肤科医生加权平均NNB为7.5,澳大利亚全科医生为14.6,美国皮肤科执业者(含皮肤科医生和高级实践专业人员)为13.2。
- 研究分层A(所有活检皮肤肿瘤)中平均4%的活检显示黑色素瘤(ES 0.04,95%CI 0.03-0.05)。
- 研究分层B(病理 review 的黑色素细胞肿瘤)和C(临床怀疑黑色素瘤)中平均12%的活检显示黑色素瘤(ES 0.12,95%CI 0.10-0.14;ES 0.12,95%CI 0.09-0.14)。
临床怎么用
- 临床可参考NNB指标评估黑色素瘤活检效率,但需注意全球报告差异大且缺乏标准化。
- 皮肤科医生的NNB低于全科医生和美国皮肤科执业者,提示专科培训可能影响活检选择性。
局限性
- 全科医生数据仅来自澳大利亚,限制了对其他地区全科医生NNB的推断。
- 研究间数据特征可变,部分研究以所有活检肿瘤为结构,影响NNB汇总的标准化。
- NNB指标本身缺乏统一定义和报告标准,导致全球数据异质性大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To date, no concerted effort has been made to date to evaluate the literature on number-needed-to-biopsy (NNB) metrics, particularly to account for the differences in clinician type and melanoma prevalence in certain geographic locations. OBJECTIVE: To review and synthesize worldwide data for NNB for the diagnosis of cutaneous melanoma. DATA SOURCE: MEDLINE, Embase, and PubMed databases were searched for English-language articles published worldwide from January 1, 2000, to November 28, 2018. STUDY SELECTION: A total of 46 studies were included that addressed NNB for at least 3681 clinicians worldwide and included 455 496 biopsied tumors and 29 257 melanomas; primary care practitioner (PCP) data were only available from Australia. DATA EXTRACTION AND SYNTHESIS: Articles were screened for eligibility, and possible overlapping data sets were resolved. Data extracted included clinician specialization, use of dermoscopy, geographic region and location-specific health care system, study design, number of benign tumors, number of melanomas, and NNB. The review followed the PRISMA guidelines. MAIN OUTCOME AND MEASURES: The NNB for the diagnosis of cutaneous melanoma. RESULTS: A total of 46 studies were included that addressed NNB for at least 3681 clinicians worldwide and included 455 496 biopsied tumors and 29 257 melanomas; primary care practitioner (PCP) data were only available from Australia. The reported NNB ranged from 2.2 to 287, and the weighted mean NNB for all included publications was 15.6. The exclusion of publications structured as all biopsied tumors, owing to variable data characterization, resulted in reported NNB ranging from 2.2 to 30.5, with a global weighted mean NNB of 14.8 for all clinicians, 7.5 for all dermatologists, 14.6 for Australian PCPs, and 13.2 for all US-based dermatological practitioners, including dermatologists and advanced practice professionals. The summary effect size (ES) demonstrates that a mean 4% of biopsies demonstrated melanoma for study stratum A (all biopsied skin tumors, ES, 0.04; 95% CI, 0.03-0.05), and a mean 12% of biopsies demonstrated melanoma for study strata B (melanocytic tumors on pathology review, ES, 0.12; 95% CI, 0.10-0.14) and C (clinical concern for melanoma, ES; 0.12; 95% CI, 0.09-0.14). CONCLUSIONS AND RELEVANCE: The existing NNB for cutaneous melanoma appeared to vary widely worldwide, lacking standardization in the metric and its reporting, and according to clinician characteristics as well; the NNB of US-based clinicians may warrant further exploration.
引用
- Nelson KC, Swetter SM, Saboda K, et al. Evaluation of the Number-Needed-to-Biopsy Metric for the Diagnosis of Cutaneous Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019. PMID: 31290958. doi:10.1001/jamadermatol.2019.1514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。